1
SOCRA Clinical Research Certification Exam
Practice Review Official Practice Exam Actual
Exam 2026/2027 with Detailed Rationales |
Complete Exam-Style Questions | Pass
Guaranteed – A+ Graded
Q1: According to ICH E6 (R2) GCP Guidelines, what is the PRIMARY
responsibility of the Institutional Review Board (IRB)?
A. To ensure the scientific validity of the study design
B. To protect the rights, safety, and well-being of human subjects
C. To monitor the financial aspects of clinical trial conduct
D. To train investigators on regulatory requirements
B. To protect the rights, safety, and well-being of human subjects [CORRECT]
Correct Answer: B
Rationale: The IRB's primary function under ICH GCP is to safeguard the rights,
safety, and welfare of human subjects involved in research by reviewing and
approving protocols, informed consent documents, and monitoring ongoing studies
for subject protection.
Q2: A sponsor receives an unexpected death report from a site 72 hours after the
event occurred. Under FDA regulations, within what timeframe must this Serious
Adverse Event (SAE) be reported to the FDA for an IND study?
,2
A. 7 calendar days
B. 10 calendar days
C. 15 calendar days [CORRECT]
D. 30 calendar days
Correct Answer: C
Rationale: FDA regulations (21 CFR 312.32) require sponsors to report fatal or
life-threatening suspected adverse reactions to the FDA as soon as possible but no
later than 15 calendar days after initial receipt of information by the sponsor.
Q3: Which document is considered the foundation of Good Clinical Practice and
establishes ethical principles for human subject protection?
A. Declaration of Helsinki
B. Belmont Report
C. Nuremberg Code
D. All of the above contribute [CORRECT]
Correct Answer: A
Rationale: The Declaration of Helsinki is the foundational international ethics
document specifically referenced in ICH GCP guidelines that establishes ethical
principles for medical research involving human subjects and serves as the primary
basis for GCP requirements worldwide.
,3
Q4: During a monitoring visit, you discover that informed consent was obtained
AFTER the subject had already undergone study procedures. What type of
deviation is this?
A. Minor protocol deviation
B. Administrative error
C. Major protocol violation [CORRECT]
D. Documentation error
Correct Answer: C
Rationale: Obtaining consent after procedures have been performed constitutes a
major protocol violation because it represents a serious breach of subject rights
under federal regulations (45 CFR 46) and ICH GCP, requiring immediate
reporting to the IRB and potentially the sponsor.
Q5: What is the MINIMUM retention period for essential documents according to
ICH E6 (R2) GCP Guidelines?
A. 2 years after marketing approval
B. 2 years after last approval of marketing application OR trial discontinuation
[CORRECT]
C. 5 years after study completion
D. 15 years permanently
Correct Answer: B
, 4
Rationale: ICH E6 (R2) Section 4.9 specifies that the investigator/institution
should retain all essential documents for at least 2 years after the last approval of a
marketing application in an ICH region and until there are no pending or
contemplated marketing applications or at least 2 years have elapsed since formal
discontinuation of clinical development.
Q6: A Phase III clinical trial is BEST characterized by which feature?
A. First-time testing in humans
B. Safety and tolerability assessment in healthy volunteers
C. Large-scale efficacy and safety evaluation in target population [CORRECT]
D. Post-marketing surveillance
Correct Answer: C
Rationale: Phase III trials are large-scale, randomized controlled studies conducted
in the intended patient population to confirm therapeutic benefit, monitor adverse
reactions in larger populations, and collect data to support regulatory approval and
labeling claims.
Q7: Under HIPAA Privacy Rule, which of the following would NOT require
authorization for use or disclosure of Protected Health Information (PHI) for
research purposes?
A. Disclosure to a researcher for analysis
B. Use of PHI to recruit potential subjects
C. Disclosures preparatory to research without direct contact [CORRECT]
D. Publication of research results containing identifiers
SOCRA Clinical Research Certification Exam
Practice Review Official Practice Exam Actual
Exam 2026/2027 with Detailed Rationales |
Complete Exam-Style Questions | Pass
Guaranteed – A+ Graded
Q1: According to ICH E6 (R2) GCP Guidelines, what is the PRIMARY
responsibility of the Institutional Review Board (IRB)?
A. To ensure the scientific validity of the study design
B. To protect the rights, safety, and well-being of human subjects
C. To monitor the financial aspects of clinical trial conduct
D. To train investigators on regulatory requirements
B. To protect the rights, safety, and well-being of human subjects [CORRECT]
Correct Answer: B
Rationale: The IRB's primary function under ICH GCP is to safeguard the rights,
safety, and welfare of human subjects involved in research by reviewing and
approving protocols, informed consent documents, and monitoring ongoing studies
for subject protection.
Q2: A sponsor receives an unexpected death report from a site 72 hours after the
event occurred. Under FDA regulations, within what timeframe must this Serious
Adverse Event (SAE) be reported to the FDA for an IND study?
,2
A. 7 calendar days
B. 10 calendar days
C. 15 calendar days [CORRECT]
D. 30 calendar days
Correct Answer: C
Rationale: FDA regulations (21 CFR 312.32) require sponsors to report fatal or
life-threatening suspected adverse reactions to the FDA as soon as possible but no
later than 15 calendar days after initial receipt of information by the sponsor.
Q3: Which document is considered the foundation of Good Clinical Practice and
establishes ethical principles for human subject protection?
A. Declaration of Helsinki
B. Belmont Report
C. Nuremberg Code
D. All of the above contribute [CORRECT]
Correct Answer: A
Rationale: The Declaration of Helsinki is the foundational international ethics
document specifically referenced in ICH GCP guidelines that establishes ethical
principles for medical research involving human subjects and serves as the primary
basis for GCP requirements worldwide.
,3
Q4: During a monitoring visit, you discover that informed consent was obtained
AFTER the subject had already undergone study procedures. What type of
deviation is this?
A. Minor protocol deviation
B. Administrative error
C. Major protocol violation [CORRECT]
D. Documentation error
Correct Answer: C
Rationale: Obtaining consent after procedures have been performed constitutes a
major protocol violation because it represents a serious breach of subject rights
under federal regulations (45 CFR 46) and ICH GCP, requiring immediate
reporting to the IRB and potentially the sponsor.
Q5: What is the MINIMUM retention period for essential documents according to
ICH E6 (R2) GCP Guidelines?
A. 2 years after marketing approval
B. 2 years after last approval of marketing application OR trial discontinuation
[CORRECT]
C. 5 years after study completion
D. 15 years permanently
Correct Answer: B
, 4
Rationale: ICH E6 (R2) Section 4.9 specifies that the investigator/institution
should retain all essential documents for at least 2 years after the last approval of a
marketing application in an ICH region and until there are no pending or
contemplated marketing applications or at least 2 years have elapsed since formal
discontinuation of clinical development.
Q6: A Phase III clinical trial is BEST characterized by which feature?
A. First-time testing in humans
B. Safety and tolerability assessment in healthy volunteers
C. Large-scale efficacy and safety evaluation in target population [CORRECT]
D. Post-marketing surveillance
Correct Answer: C
Rationale: Phase III trials are large-scale, randomized controlled studies conducted
in the intended patient population to confirm therapeutic benefit, monitor adverse
reactions in larger populations, and collect data to support regulatory approval and
labeling claims.
Q7: Under HIPAA Privacy Rule, which of the following would NOT require
authorization for use or disclosure of Protected Health Information (PHI) for
research purposes?
A. Disclosure to a researcher for analysis
B. Use of PHI to recruit potential subjects
C. Disclosures preparatory to research without direct contact [CORRECT]
D. Publication of research results containing identifiers
